This executive order directs the secretary of Health and Human Services, through the commissioner of Food and Drugs (FDA Commissioner), to take steps to eliminate any duplicative or unnecessary requirements that pertain to the approval, development or expansion of domestic pharmaceutical manufacturing facilities. It also directs the FDA Commissioner to develop and advance improvements to the inspection of foreign manufacturing facilities that supply medicines to the United States.